(Q34067633)

30 July 2017

1 reference

title

Adjuvant therapy in melanoma. (English)

1 reference

30 July 2017

Whittaker S

1

1 reference

30 July 2017

publication date

1 September 2000

1 reference

Clinical and Experimental Dermatology

30 July 2017

published in

1 reference

30 July 2017

volume

25

1 reference

30 July 2017

issue

6

1 reference

30 July 2017

page(s)

497-502

1 reference

Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2000.00704.X

A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2000.00704.X

Newer strategies for effective evaluation of primary melanoma and treatment of stage III and IV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2000.00704.X

Interferons in the treatment of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2000.00704.X

Interferon alfa-2a therapy for life-threatening hemangiomas of infancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2000.00704.X

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2000.00704.X

Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2000.00704.X

Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2000.00704.X

Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2000.00704.X

Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2000.00704.X

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2000.00704.X

10.1046/J.1365-2230.2000.00704.X

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference